The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases

  • Jani M
  • Barton A
  • Warren R
 et al. 
  • 104


    Mendeley users who have this article in their library.
  • 82


    Citations of this article.


The management of RA, SpA, psoriasis and inflammatory bowel disease has significantly improved over the last decade with the addition of tumour necrosis factor inhibitors (anti-TNFs) to the therapeutic armamentarium. Immunogenicity in response to monoclonal antibody therapies (anti-drug antibodies) may give rise to low serum drug levels, loss of therapeutic response, poor drug survival and/or adverse events such as infusion reactions. To combat these, the use of concomitant MTX may attenuate the frequency of anti-drug antibodies in RA, SpA and Crohn's disease. Although a similar effect to methotrexate has been observed with AZA usage in the management of Crohn's disease, there is insufficient evidence to suggest that other DMARDs impact immunogenicity. In this article we review the evidence to date on the effect of immunomodulatory therapy when co-administered with anti-TNFs. We also discuss whether such a strategy should be employed in SpA and psoriasis, and if optimization of the MTX dose could improve biologic drug survival and thereby benefit disease management.

Author-supplied keywords

  • Anti-TNFs
  • Anti-drug antibodies
  • Azathioprine
  • Biologics
  • Disease-modifying anti-rheumatic drugs
  • Immunogenicity
  • Methotrexate

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Hector ChinoyUniversity of Manchester

  • Meghna Jani

  • Anne Barton

  • Richard B. Warren

  • Christopher E.M. Griffiths

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free